Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
The Journal of Infectious Diseases|March 16, 2011
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trialsPeter B Gilbert, James O Berger, Donald Stablein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2009
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1Graeme Moyle, Edwin DeJesus, Marta Boffito, et al.
Addiction (Abingdon, England)|August 10, 2018
Independent predictors of mortality in adolescents ascertained for conduct disorder and substance use problems, their siblings and community controlsRichard Border, Robin P Corley, Sandra A Brown, et al.
Plos Pathogens|August 7, 2023
Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2Gary Ewart, Michael Bobardt, Bo Hjorth Bentzen, et al.
Nature|November 12, 2025
Estimation and mapping of the missing heritability of human phenotypesPierrick Wainschtein, Yuanxiang Zhang, Jeremy Schwartzentruber, et al.
The Journal of Antimicrobial Chemotherapy|March 14, 2007
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimenD William Cameron, Stephen Becker, Martin S King, et al.
Disease Markers|July 20, 2004
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancersChristine Laronga, Stephen Becker, Patrice Watson, et al.
The Journal of Infectious Diseases|October 10, 2020
Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell ModulationCarolyn A Luscombe, Anchalee Avihingsanon, Khuanchai Supparatpinyo, et al.
AIDS Research and Human Retroviruses|May 18, 2019
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210Victoria A Johnson, Yoninah S Cramer, Susan L Rosenkranz, et al.
European Journal of Human Genetics : EJHG|February 7, 2019
Imputation of behavioral candidate gene repeat variants in 486,551 publicly-available UK Biobank individualsRichard Border, Andrew Smolen, Robin P Corley, et al.
Pageof 8